Biologics CDMO Market, By Type (Mammalian, Non-Mammalian), By Product Type (Biologics (Recombinant Proteins, Vaccines, Monoclonal, Antisense & Molecular Therapy, and Other Biologics) and Biosimilars), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Biologics CDMO  Market was valued at US$ 18 Billion in 2024 and is projected to grow at a CAGR of 11.80% to reach US$ 55 Billion by 2034.

Biologics has become a powerful drugs which slows down inflammation that damage joints and other organs in arthritis and inflammatory diseases. Biologics CDMO (contract development and manufacturing organization), offers biological medical product development & manufacturing services for pharmaceutical industries.

Growing prevalence of chronic diseases and growth in ageing population has contributed in market growth. Growing demand for novel therapies and need for huge capital investment for innovative & advanced technologies in pharmaceutical companies is further expected to provide lucrative opportunities in Biologics CDMO market growth.

Rising prevalence of cancer diseases to fuel market growth

The rising prevalence of cancer diseases has become a major factor in Biologics CDMO market growth. Different types of cancer are on the rise due to poor and unhealthy lifestyles. Breast cancer, lung cancer, liver and kidney cancer, and pancreatic cancer are on the rise. Cancer therapies has become the major driver for large portion of growth in Biologics CDMO market. For instance, according to Center for Disease and Control and Prevention (CDC), In the United States in 2019, 1,752,735 new cancer cases were reported and 599,589 people died of cancer. For every 100,000 people, 439 new cancer cases were reported and 146 people died of cancer.

Rising demand for CDMOs from emerging pharmaceutical and biotech companies

Rising demand for CDMOs from emerging pharmaceutical and biotech companies has boosted the target market's growth. The rise in the number of clinical trials has become a major driver of target market expansion. According to Food and Drug Administration (FDA) there are around 50 ongoing clinical trials in cell and gene therapy by major and emerging biotech or pharmaceutical companies. Further, outsourcing provides advantages such as a reduction in investment risks, expert knowledge, advance tools and technology, increasing productivity and efficiency, reducing labor work, and ideal for startups and small businesses. Rising demand for novel biologics has given rise to CAGT (Cell & Gene Therapy) one of the fastest-growing areas of the biopharmaceutical industry. As till January 2023, Food and Drug Administration (FDA) has approved 621 biologics products.

For instance, Samsung Biologics a fully integrated CDMO company received more than 50 drug approvals after 30 times inspection by regulatory authorities. The company provides quality-based manufacturing and lab testing services with innovative technologies and fulfill the demand of biopharmaceutical industries. The company has three manufacturing plants by 2017 which in-house around 364,000L of mammalian cell culture with largest antibody manufacturing capacity.                                               

Restrains:

Some challenges faced by CDMOs, are cost pressure, fierce competition, consolidation, and constant technological innovations, which may hamper the market growth. The wrong innovative CDMO solution provider may lead to a bad customer experience and variations in the standards of customer service may lead to quality problems. Further, it may also may lead to less control over the production process, which act as a challenges and disadvantages of CDMOs which in turn hampered the demand for Biologics CDMO market growth.

Biologics CDMO Market is segmented based on Type, Product Type, and Region.

Type Insight

On the basis of Type, Biologics CDMO Market is segmented into Mammalian, Non-Mammalian. Mammalian type segment is expected to dominate the target market growth as they are used to produce recombinant human proteins and also used for manufacturing biological products such as enzymes, synthetic hormones and antibodies.

Product Type Insights

On the basis of Product Type, Biologics CDMO Market is segmented into Biologics (Recombinant Proteins, Vaccines, Monoclonal, Antisense & Molecular Therapy, and Other Biologics) and Biosimilars. Biologics product type segment is expected to dominate the target market growth due to its benefits and potentiality to treat various medical conditions where no other treatment is available.

Regional Insights:

On region the Biologics CDMO Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period owing to rising prevalence of chronic and cancer diseases, advanced healthcare infrastructure along with increased awareness about biologics such as cell and gene therapy, growing research & development activities, presence of major key players is anticipated to increase demand for Biologics CDMO in the region.

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Biologics CDMO Market report based on Type, Product Type, and Region.

Biologics CDMO Market, By Type:

• Mammalian
• Non-Mammalian

Biologics CDMO Market, By Product Type:

• Biologics

• Recombinant Proteins
• Vaccines
• Monoclonal
• Antisense & Molecular Therapy
• Other Biologics

• Biosimilars

Biologics CDMO Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Biologics CDMO Market includes, Lonza Group, Catalent Inc., Samsung Biologics, Eurofins Scientific, Boehringer Ingelheim Group, FUJIFILM Diosynth Biotechnologies Inc., Wuxi Biologics, LabCorp Drug Development, Cambrex Corporation, AGC Biologics and others.

Report Scope:

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Type - Mammalian, Non-Mammalian By Product Type - Biologics and Biosimilars
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Recent Development:

• In March 2023, Samsung Biologics signed a deal Pfizer to manufacture COVID-19 vaccines for Moderna. The value of the contract is $183 million and will run through the year 2029. This new deal worth 15% of Samsung’s $1.2 billion revenue from 2021 year.
• In March 2023, Takeda planned to invest around $765 million to develop new production facility in Osaka, Japan. This new plant will help to expand Takeda’s largest plasma-based manufacturing capacity in operation by year 2030.
• In July 2022, Lonza has planned to spend $518 million on a large-scale fill-finish manufacturing plant in Stein, Switzerland. A new manufacturing plant is expected to be completed in 2026. This plant will offer integrated, end-to-end CDMO services

• Lonza Group*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Catalent Inc.
• Samsung Biologics
• Eurofins Scientific
• Boehringer Ingelheim Group
• FUJIFILM Diosynth Biotechnologies Inc.
• Wuxi Biologics
• LabCorp Drug Development
• Cambrex Corporation
• AGC Biologics

“*” marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for medical carts Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Type
     • Market Snippet, By Product Type
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restrains
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Market Segmentation, By Type
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Mammalian
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Non-Mammalian
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
6. Market Segmentation, By Product Type, 2022 – 2032, (US$ Bn)
   • Overview                                      
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Biologics
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Biosimilars
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
7. Global Market, By Region, 2022 – 2032, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Product Type, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Product Type, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • UK
       • France
       • Germany
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Product Type, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific

The Last Word

• Future Impact
• About Us
• Contact

Samsung Biologics

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

Eurofins Scientific

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

Boehringer Ingelheim Group

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

FUJIFILM Diosynth Biotechnologies Inc.

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

Wuxi Biologics

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

LabCorp Drug Development

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

Cambrex Corporation

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

AGC Biologics

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

Lonza Group

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

Catalent Inc.

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

 

•  
  •  
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East

Competitive Landscape

• Heat Map Analysis
• Market Presence and Specificity Analysis

Company Profiles

 

• Rest of Latin America
  • Mexico
  • Brazil
• Middle East & Africa
  • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
  • Market Size and Forecast (US$ Bn), By Product Type, 2022 – 2032
  • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032Latin America
    • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Product Type, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032